Similarly, among patients with metastatic colorectal cancer (mCRC), a RAS mutation is used as a predictive biomarker to select patients who will not benefit from epidermal growth factor receptor (EGFR) antibody therapy [9,10,11]. This evidence concerns the gene EGFR and metastatic colorectal cancer.